WiseTech Global Limited (ASX: WTC)
WiseTech Global Limited (ASX: WTC), on 26 May 2025 announced it will acquire U.S based E2open Parent Holdings for $3.30 per share in cash, totalling an enterprise value of $2.1 billion. This fully debt funded transaction is expected to close in the first half of FY26, pending regulatory approvals. The acquisition supports WTC’s vision to become the operating system for global trade and logistics by expanding into adjacent markets and creating a multi-sided trade and logistics marketplace. E2open adds complementary product capabilities, connects a network of 500,000 enterprises and increases integration across global supply chains.
WTC achieved strong results for the 1H of FY25. Total revenue reached $381.0 million, CargoWise revenue was $331.7 million and EBITDA came in at $192.3 million, showing YoY growth. Underlying NPAT was $112.1M and statutory NPAT was $106.4M. Operating cash flow rose to $202.7 million and free cash flow to $124.1 million. The interim dividend increased to 6.7cps. FY25 earnings guidance remains unchanged apart from $40 million in one-time transaction costs due to the e2open deal. More financial updates will be shared in August 2025.
The company advanced its 3P strategy (Product, Penetration, and Profitability). It launched ComplianceWise and CargoWise Next, while Container Transport Optimization is set for initial rollout in Australia in the second half. R&D investment improved to $137.0M. Two new Large Global Freight Forwarders, Nippon Express and LOGISTEED were secured, bringing total rollouts to 54. Recent acquisitions BSM and ImpexDocs improved capabilities in digital documentation.
Pro Medicus Ltd (ASX: PME)
Pro Medicus Limited (ASX: PME) achieved decent interim results for the half year ending December 2024. Revenue rose 31.1% to $97.2 million and net profit reached $51.7 million, a 42.7% increase. Underlying profit before tax was $69.9 million, up 42.9%. EBIT margins improved to 72% compared to 66% in the prior corresponding period. PME remains debt free and declared a fully franked interim dividend of 25 cps. North American operations were an important driver of growth contributing $86.4M in revenue, a 34.6% rise.
Several contracts were secured during the period. New agreements were signed with Trinity Health, Lurie Children’s Hospital and Duly Health and Care, amounting to a combined $365 million across terms ranging from 7 to 10 years. Renewals were completed with Mercy Health for $98 million over 8 years and an Australian radiology group for $32 million across 5 years. Existing client relationships were more expanded through archive module additions worth $15 million over 5 years for Duke Health and $24 million over 5 years for NYU Langone.
In March 2025, a $40 million, 7year deal was signed with LucidHealth, a radiology service provider in the US. In April 2025, a multi-year research collaboration was established with UCSF focused on AI development using the Visage AI Accelerator platform. In May 2025, a $20 million, 5-year contract was confirmed with University of Iowa Health Care for a cloud-based enterprise imaging platform rollout.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
